Select Language
Free Registration

HLA-E*0103 | B2M

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TesnatilimabIPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555Phase 2 ClinicalInnate PharmaAlopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease
Details
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)Phase 2 ClinicalCoronavirus Disease 2019 (COVID-19)
Details
QEQ-278QEQ-278Phase 1 ClinicalNovartis Pharmaceuticals CorpSquamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung
Details
NKG2D CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdColorectal Neoplasms; Leukemia, Myeloid, Acute
Details
NKG2D CAR-T cell therapy (Uwell Biopharma)UWN2DClinicalUwell BiopharmaNeoplasms
Details
  • Product Inquiry
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland